Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06208189
Other study ID # 2310089095
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date July 2024

Study information

Verified date March 2024
Source University of New Mexico
Contact Flavio De Castro Magalhaes, PhD
Phone 1(505)277-2664
Email fcm@unm.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the degree of effort during a resistance exercise session on blood glucose levels in individuals with prediabetes or type 2 diabetes mellitus. The main questions it aims to answer are: - Do individuals with prediabetes or type 2 diabetes mellitus need to perform resistance exercise with a high degree of effort for their blood glucose to improve? - How do they feel (their enjoyment, discomfort) after the sessions with different degrees of effort? Participants will perform 3 situations separated by at least 4 days, after being familiarized with all exercises and procedures: - One control day, when they will not exercise; - A high-effort resistance exercise session; - A low-effort resistance exercise session Researchers will measure blood glucose levels and psychological responses after these situations to see if the effort was important for the improvement of their blood glucose and how effort affected the way they felt after each situation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - age between 18 and 75 years; - presence of prediabetes (fasting glycemia between 100 and 125 mg/dL or glycated hemoglobin [A1c] between 5.7 and 6.4%) or T2DM (fasting glycemia 126 mg/dL or above or A1c 6.5% or above). Exclusion Criteria: - renal failure, - liver disease, - uncontrolled hypertension (equal or greater than 160 mmHg systolic and/or equal or greater than 100 mmHg diastolic), - history of severe cardiovascular problems, - in case of oral hypoglycemic drugs usage, being on them for less than 6 months, - inability to perform resistance exercise, - being pregnant or trying to become pregnant during the course of the study, - use of oral contraceptives, - prisoners, - persons requiring a legally authorized representative, - non-English speakers.

Study Design


Intervention

Behavioral:
High-effort session
Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform ~10 repetitions per set in this session, with a total tempo of ~2.5 seconds per rep, averaging ~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of ~50 min. Their glycemic control will be evaluated during the following ~48 hours.
Low-effort session
Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at ~2.5 seconds will result in ~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of ~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following ~48 hours.
Control
The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following ~48 hours.

Locations

Country Name City State
United States UNM Exercise Physiology Lab Albuquerque New Mexico

Sponsors (1)

Lead Sponsor Collaborator
University of New Mexico

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose concentration Average glucose concentration (measured in milligrams per deciliter of blood, with a continuous glucose monitoring device) For 48 hours during each situation (arm) of the study
Primary Glucose concentration Average glucose concentration (measured in milligrams per deciliter of blood, with a continuous glucose monitoring device) For 6 hours during the morning (6 am - 12 pm) of each situation (arm) of the study
Primary Glucose concentration Average glucose concentration (measured in milligrams per deciliter of blood, with a continuous glucose monitoring device) For 6 hours during the afternoon (12 pm - 6 pm) of each situation (arm) of the study
Primary Glucose concentration Average glucose concentration (measured in milligrams per deciliter of blood, with a continuous glucose monitoring device) For 6 hours during the evening (6 pm - 12 am) of each situation (arm) of the study
Primary Glucose concentration Average glucose concentration (measured in milligrams per deciliter of blood, with a continuous glucose monitoring device) For 6 hours during the nocturnal period (12 am - 6 am) of each situation (arm) of the study
Primary Time in range Time of glucose concentration between 70 and 180 mg/dL (measured in minutes) For 48 hours during each situation (arm) of the study
Primary Time in range Time of glucose concentration between 70 and 180 mg/dL (measured in minutes) For 6 hours during the morning (6 am - 12 pm) of each situation (arm) of the study
Primary Time in range Time of glucose concentration between 70 and 180 mg/dL (measured in minutes) For 6 hours during the afternoon (12 pm - 6 pm) of each situation (arm) of the study
Primary Time in range Time of glucose concentration between 70 and 180 mg/dL (measured in minutes) For 6 hours during the evening (6 pm - 12 am) of each situation (arm) of the study
Primary Time in range Time of glucose concentration between 70 and 180 mg/dL (measured in minutes) For 6 hours during the nocturnal period (12 am - 6 am) of each situation (arm) of the study
Primary Prevalence of hyperglycemia Time of glucose concentrations >180 mg/dL (measured in minutes) For 48 hours during each situation (arm) of the study
Primary Prevalence of hyperglycemia Time of glucose concentrations >180 mg/dL (measured in minutes) For 6 hours during the morning (6 am - 12 pm) of each situation (arm) of the study
Primary Prevalence of hyperglycemia Time of glucose concentrations >180 mg/dL (measured in minutes) For 6 hours during the afternoon (12 pm - 6 pm) of each situation (arm) of the study
Primary Prevalence of hyperglycemia Time of glucose concentrations >180 mg/dL (measured in minutes) For 6 hours during the evening (6 pm - 12 am) of each situation (arm) of the study
Primary Prevalence of hyperglycemia Time of glucose concentrations >180 mg/dL (measured in minutes) For 6 hours during the nocturnal period (12 am - 6 am) of each situation (arm) of the study
Primary Prevalence of hypoglycemia Time of glucose concentrations <70 mg/dL (measured in minutes) For 48 hours during each situation (arm) of the study
Primary Prevalence of hypoglycemia Time of glucose concentrations <70 mg/dL (measured in minutes) For 6 hours during the morning (6 am - 12 pm) of each situation (arm) of the study
Primary Prevalence of hypoglycemia Time of glucose concentrations <70 mg/dL (measured in minutes) For 6 hours during the afternoon (12 pm - 6 pm) of each situation (arm) of the study
Primary Prevalence of hypoglycemia Time of glucose concentrations <70 mg/dL (measured in minutes) For 6 hours during the evening (6 pm - 12 am) of each situation (arm) of the study
Primary Prevalence of hypoglycemia Time of glucose concentrations <70 mg/dL (measured in minutes) For 6 hours during the nocturnal period (12 am - 6 am) of each situation (arm) of the study
Secondary Resistance Training Intensity by the Omni Perceived Exertion Scale Discrete scale from 0 to 10, where higher values mean more perceived exertion. After each set of each exercise performed.
Secondary Feeling scale Discrete scale from -5 to +5, where higher values mean more positive feelings. Before and immediately after the resistance exercise sessions.
Secondary Physical Activity Enjoyment Scale Scale composed of 18 items, with scores from 1 to 7 each (total score from 18 to 126). After analysis, higher scores mean higher enjoyment. Immediately after the resistance exercise sessions.
Secondary Self-efficacy scale Scale composed of 8 questions, with discrete options from 0 to 100%. Higher scores mean higher self-efficacy. Immediately after the resistance exercise sessions.
Secondary Rating of Discomfort scale Discrete scale from 0 to 100, where higher scores mean more discomfort. Before and 5 minutes after the resistance exercise sessions.
Secondary Session rating of perceived exertion Discrete scale from 0 to 10, where higher values mean more perceived exertion. 5 minutes after the resistance exercise sessions.
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Recruiting NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance